Memantine properties

Moryl E, Danysz W, Quack G (1993) Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 72 394-397 NaassUa M, Hammoumi S, Legrand E, et al (1998) Mechanism of action of acamprosate. Part 1. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcoholism 22 802-809... 

MEMANTINE ANTIMUSCARINICS Possible t efficacy of antimuscarinics Additive effect memantine has weak antimuscarinic properties Warn patients of this effect... 

Danysz, W., Gossel, M., Zajaczkowski, W., Dill, D., Quack, G. (1994). Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats Case of amantadine and memantine. J. Neurol. Transm. Park. Dis. Dement. Sect. 1 155-66. 

Among promising candidates as antidotes against CNS intoxication by OP nerve agents, memantine (MEM) has been shown to pose both anti-excitotoxic and anti-epileptic properties. Memantine is an uncompetitive NMDA receptor antagonist, clinically used for the treatment of Alzheimer s disease, Parkinson s disease and spasticity, in the absence of serious side effects (Ozsuer et al, 2005 Lipton, 2005). From a series of rat in vivo experiments, it is evident that pre-administration of memantine significantly protects... 

HYDROXYTRYPTAMINE RECEPTOR AGONIST that has PSYCHOTROPIC (hallucinogenic) properties, dimethoxystrychnine brucine, dimethyladamantanamine memantine, dimethylbiochanin B daidzein. P-dimethylcysteine penicillamine. 

A study conducted in Germany indicates that kava may have neuroprotective properties, primarily owing to its constituent methysticum and dihydromethysticum (18). The investigators studied the effects of kava extract WS 1490 and the individual pyrones kavain, dihydrokavain, methysticin, dihydromethysticin, and yangonin on the size of infarction in mouse brains. The extract as well as the individual pyrones methysticin and dihydromethysticin showed significant reductions in infarct area similar to those produced by memantine, an anticonvulsive agent known to have neuroprotective qualities (18). 

Memantine is a colorless to white crystalline substmice readily soluble in water. Its oral bioavailability is nearly 1(X)%. Memantine readily crosses the blood-brain barrier, and while in organism ii shows linear, dose-proportional pharmacokinetics and weak protein-binding properties. 

Serendipitous ob.servation of beneficial effects of aminoadamantanes in Parkinson s disease patients undergoing antiviral therapy led to the conclusion that these tompound.s may pos.sess dopaminomimetic or possibly cholinoiytic properties. The fact that administration of clinically relevant do.ses of memantine results primarily in NMDA receptor antagonism was discovered only in the late 1980s (Bormann, 1989). 

Holler, S, M., Danysz. W., and Spanagel, R. (1996). Evidence for alcohol anti-craving properties of memantine, Eur. J. Pharmacol. 314, RI-R2. 

Moryl, E., Danysz, W.. and Quack, G. (199.3). Potential antidepres-sivc properties of amantadine, memantine and hil cmelanc. Pharmacol. Toxicol. 72, 394-397. 

Ketamine is one of the most widely known and medically used NMDA receptor antagonists (NMDAR) and memantine is similar in that it is a noncompetitive NMDA antagonist but is better tolerated in patients because of multiple theorized properties including the ability to bind only (or preferentially) to open channels the tendency to inhibit faster, or with higher affinity, at higher agonist concentration a relatively low affinity of inhibition being an open channel blocker with a fast off-rate compared with ketamine [1,2]. 

---